Active surveillance as a treatment option for metastatic or recurrent renal cell carcinoma.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Inkeun | - |
dc.contributor.author | Lee, Jae-Lyun | - |
dc.contributor.author | Ahn, Jin-Hee | - |
dc.contributor.author | Jeong, In Gab | - |
dc.contributor.author | Song, Cheryn | - |
dc.contributor.author | Hong, Bum-Sik | - |
dc.contributor.author | Hong, Jun Hyuk | - |
dc.contributor.author | Kim, Choung-Soo | - |
dc.contributor.author | Ahn, Hanjong | - |
dc.date.available | 2020-02-28T18:41:51Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2014-02-01 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/12843 | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | AMER SOC CLINICAL ONCOLOGY | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL ONCOLOGY | - |
dc.title | Active surveillance as a treatment option for metastatic or recurrent renal cell carcinoma. | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000335318100424 | - |
dc.identifier.doi | 10.1200/jco.2014.32.4_suppl.426 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL ONCOLOGY, v.32, no.4 | - |
dc.citation.title | JOURNAL OF CLINICAL ONCOLOGY | - |
dc.citation.volume | 32 | - |
dc.citation.number | 4 | - |
dc.contributor.affiliatedAuthor | Park, Inkeun | - |
dc.type.docType | Meeting Abstract | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.